4-Tert-butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester | 204691-62-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Tert-butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester
• 英文别名: benzyl 4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-oxopiperazine-1-carboxylate
• CAS: 204691-62-3
• 化学式: C₁₈H₂₄N₂O₅
• 分子量: 348.399
• InChiKey: BNEGWAMZLRSUBB-UHFFFAOYSA-N

物化性质

• 沸点：
  510.1±50.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-Tert-butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester 在 palladium on activated charcoal TEA 、 氢气 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 [4-(6-Chlorobenzo[b]thiophene-2-sulfonyl)-2-oxopiperazine-1-yl]acetic acid
  参考文献：
  名称：

  Nonbenzamidine compounds as selective factor xa inhibitors

  摘要：

  Nonbenzamidine compounds (imidazole, pyridine, pyrimidine, and thiazole derivatives) as selective serine protease factor Xa inhibitors are discussed. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00316-4
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 4-Cbz-2-哌嗪酮 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以97%的产率得到4-Tert-butoxycarbonylmethyl-3-oxopiperazine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

  摘要：

  We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor. This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker. The SARM -nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase. This leads to the ubiquitination of the androgen receptor, and its subsequent degradation by the proteasome. Upon treatment of HeLa cells with 10 mu M PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels. This degradation is proteasome dependent, as it is mitigated in cells pre-treated with 10 mu M epoxomicin, a specific proteasome inhibitor. These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.114

文献信息

• Substituted oxoazaheterocyclyl compounds
  申请人：AVENTIS PHARMACEUTICALS INC.

  公开号：US20040102450A1

  公开（公告）日：2004-05-27

  This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

  这项发明涉及抑制因子Xa的氧杂杂环化合物，抑制同时抑制因子Xa和因子IIa的氧杂杂环化合物，包含这些化合物的药物组合物，用于制备这些化合物的中间体，直接抑制因子Xa的方法，以及同时直接抑制因子Xa和因子IIa的方法。
• [EN] SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS<br/>[FR] COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUES INHIBITEURS DU FACTEUR Xa
  申请人：AVENTIS PHARMACEUTICALS PRODUCTS INC.

  公开号：WO1999037304A1

  公开（公告）日：1999-07-29

  (EN) This invention is directed to oxoazaheterocyclyl compounds which inhibit factor Xa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of inhibiting factor Xa.(FR) L'invention porte sur des composés oxoazahétérocyclyle qui inhibent le facteur Xa, sur des compositions pharmaceutiques comprenant ces composés, sur des intermédiaires utiles dans la préparation de ces composés et sur un procédé d'inhibition du facteur Xa.

  该发明涉及抑制因子Xa的氧杂杂环基化合物，包括这些化合物的制药组合物，有用于制备这些化合物的中间体以及一种抑制因子Xa的方法。
• [EN] SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS<br/>[FR] COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUE INHIBITEURS DU FACTEUR Xa
  申请人：AVENTIS PHARM PROD INC

  公开号：WO2000032590A1

  公开（公告）日：2000-06-08

  This invention is directed to oxoazaheterocyclyl compounds which inhibit factor Xa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of inhibiting factor Xa.

  本发明涉及抑制因子Xa的氧杂杂环化合物，包括这些化合物的制药组合物，制备这些化合物的中间体和抑制因子Xa的方法。
• [EN] DEGRADER COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE DÉGRADATION ET LEURS UTILISATIONS
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2022271727A1

  公开（公告）日：2022-12-29

  Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于降解蛋白酪氨酸磷酸酶（如蛋白酪氨酸磷酸酶非受体2型（PTPN2）和/或蛋白酪氨酸磷酸酶非受体1型（PTPN1））的化合物、组合物和方法，以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病（如癌症或代谢性疾病）的化合物、组合物和方法。
• SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP1051176A1

  公开（公告）日：2000-11-15